BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32002295)

  • 1. The M2 macrophage marker
    Xu ZJ; Gu Y; Wang CZ; Jin Y; Wen XM; Ma JC; Tang LJ; Mao ZW; Qian J; Lin J
    Oncoimmunology; 2020; 9(1):1683347. PubMed ID: 32002295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
    Haferlach C; Kern W; Schindela S; Kohlmann A; Alpermann T; Schnittger S; Haferlach T
    Genes Chromosomes Cancer; 2012 Mar; 51(3):257-65. PubMed ID: 22072540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
    Rockova V; Abbas S; Wouters BJ; Erpelinck CA; Beverloo HB; Delwel R; van Putten WL; Löwenberg B; Valk PJ
    Blood; 2011 Jul; 118(4):1069-76. PubMed ID: 21596848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT blockade repolarizes AML-associated TIGIT
    Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
    Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
    Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
    Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
    Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
    Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
    Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
    Baldus CD; Tanner SM; Ruppert AS; Whitman SP; Archer KJ; Marcucci G; Caligiuri MA; Carroll AJ; Vardiman JW; Powell BL; Allen SL; Moore JO; Larson RA; Kolitz JE; de la Chapelle A; Bloomfield CD
    Blood; 2003 Sep; 102(5):1613-8. PubMed ID: 12750167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
    Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
    Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
    Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
    Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
    Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
    Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
    Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis: A biomarker of high-risk phenotype in pediatric acute myeloid leukemia?
    Tyagi A; Pramanik R; Bakhshi R; Vishnubhatla S; Bakhshi S
    Int J Lab Hematol; 2019 Feb; 41(1):141-147. PubMed ID: 30383325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.